Omeprazole Treatment of Children With Peptic Esophagitis Refractory to Ranitidine Therapy

Karjoo, Manoochehr; Kane, Robert E.

doi:10.1001/archpedi.1995.02170150047007

Cited by 55 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The experience with proton pump inhibitors (omeprazole, lansoprazole) is limited. Excellent results have been reported in refractory GORD in older children at doses of 0.7 to 2.0 mg/ kg per day [1,34,54,55,69,74], while pH-metric improvement was not seen at the normal therapeutic dose in young infants [54,55,81] . The most frequent sideeffects of H 2 -receptor antagonists and proton pump inhibitors, are fatigue, dizziness, headache, dyspepsia, nausea, abdominal pain, flatulence, constipation and diarrhoea.…”

Section: Antacids H 2 -Receptor Antagonists and Proton Pump Inhibitorsmentioning

confidence: 96%

A critical appraisal of current management practices for infant regurgitation - recommendations of a working party

Vandenplas

Belli²,

Benhamou

et al. 1997

European Journal of Pediatrics

126

View full text Add to dashboard Cite

A critical appraisal of current management practices for infant regurgitation: recommendations of a working party Vandenplas, Y.; Belli, D.; Benhamou, P.; Cadramel, S.; Cezard, J.P.; Cucchiara, S.; Dupont, C.; Faure, C.; Gottrand, F.; Hassall, E.; Heymans, H.S.A.; Kneepkens, C.M.F.; Sandhu, B. Published in:European Journal of Pediatrics DOI:10.1007/s004310050613Link to publication Citation for published version (APA):Vandenplas, Y., Belli, D., Benhamou, P., Cadramel, S., Cezard, J. P., Cucchiara, S., ... Sandhu, B. (1997). A critical appraisal of current management practices for infant regurgitation: recommendations of a working party. European Journal of Pediatrics, 156, 343-357. DOI: 10.1007/s004310050613 General rightsIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Abstract Regurgitation is a common manifestation in infants below the age of 1 year and a frequent reason of counselling of general practitioners and paediatricians. Current management starts with postural and dietary measures, followed by antacids and prokinetics. Recent issues such as an increased risk of sudden infant death in the prone sleeping position and persistent occult gastrooesophageal reflux in a subset of infants receiving milk thickeners or thickened ''anti-regurgitation formula'' challenge the established approach. Therefore, the clinical practices for management of infant regurgitation have been critically evaluated with respect to their efficacy, safety and practical implications.

show abstract

Section: Antacids H 2 -Receptor Antagonists and Proton Pump Inhibitorsmentioning

confidence: 96%

A critical appraisal of current management practices for infant regurgitation - recommendations of a working party

Vandenplas

Belli²,

Benhamou

et al. 1997

European Journal of Pediatrics

126

View full text Add to dashboard Cite

show abstract

“…De Giacomo et al 44 showed endoscopic, but not histological, healing of esophagitis in 90% of treated children, symptoms improvement in 100% and a significant reduction in reflux index. Karjoo et al 45 reported symptom improvement in 87% of treated children. Gunasekaran et al 25 reported symptom resolution, esophageal acid exposure within normal range and endoscopic healing of esophagitis in 100% of children by 6 months of treatment.…”

Section: Resultsmentioning

confidence: 96%

“…After reviewing the titles and abstracts and the fulllength articles, 12 articles were selected for closer assessment and then included in our analysis. 17,18,22,[25][26][27][41][42][43][44][45][46] They are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…GERD symptom improvement or disappearance were reported as percentage of asymptomatic children in 10 studies 18,22,[25][26][27][42][43][44][45][46] and showed symptomatic response in 189 out of 235 treated children (80.4%) but rate of symptom relief widely varied ranging from 35% to 100% (Figure 1). In 2 studies 17,41 the clinical score only was reported, and was significantly decreased in 1 study.…”

Section: Resultsmentioning

confidence: 99%

“…However, when looking more carefully at the data presented the higher efficacy of omeprazole compared to ranitidine is not proven. Karjoo et al 45 initially treated children with 8 mg/kg once daily ranitidine, increasing to 12 mg/kg once daily if no symptomatic improvement was observed after 2 weeks, but this apparent failure of ranitidine could be due to a too short period of observation or, more probably, to a too low dosage of ranitidine. Indeed, when Cucchiara et al 27 directly compared omeprazole 1 mg/kg once daily to ranitidine at the dose of 20 mg/kg once daily efficacy was similar in symptom relief, endoscopic and …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review

Monzani¹,

Oderda²

2010

CEG

View full text Add to dashboard Cite

Abstract:Omeprazole is a proton-pump inhibitor indicated for gastroesophageal reflux disease and erosive esophagitis treatment in children. The aim of this review was to evaluate the efficacy of delayed-release oral suspension of omeprazole in childhood esophagitis, in terms of symptom relief, reduction in reflux index and/or intragastric acidity, and endoscopic and/or histological healing. We systematically searched PubMed, Cochrane and EMBASE (1990 to 2009) and identified 59 potentially relevant articles, but only 12 articles were suitable to be included in our analysis. All the studies evaluated symptom relief and reported a median relief rate of 80.4% (range 35%-100%). Five studies reported a significant reduction of the esophageal reflux index within normal limits (7%) in all children, and 4 studies a significant reduction of intra-gastric acidity. The endoscopic healing rate, reported by 9 studies, was 84% after 8-week treatment and 95% after 12-week treatment, the latter being significantly higher than the histological healing rate (49%). In conclusion, omeprazole given at a dose ranging from 0.3 to 3.5 mg/kg once daily (median 1 mg/kg once daily) for at least 12 weeks is highly effective in childhood esophagitis.

show abstract

Pharmacological treatment of children with gastro-oesophageal reflux

Tighe

Afzal

Bevan

et al. 2014

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Gastro-oesophageal reflux (GOR) is a common disorder, characterised by regurgitation of gastric contents into the oesophagus. GOR is a very common presentation in infancy in both primary and secondary care settings. GOR can affect approximately 50% of infants younger than three months old. The natural history of GOR in infancy is generally that of a functional, self-limiting condition that improves with age; < 5% of children with vomiting or regurgitation continue to have symptoms after infancy. Older children and children with co-existing medical conditions can have a more protracted course. The definition of gastro-oesophageal reflux disease (GORD) and its precise distinction from GOR are debated, but consensus guidelines from the North American Society of Gastroenterology, Hepatology and Nutrition define GORD as 'troublesome symptoms or complications of GOR.' Objectives This Cochrane review aims to provide a robust analysis of currently available pharmacological interventions used to treat children with GOR by assessing all outcomes indicating benefit or harm. Search methods We sought to identify relevant published trials by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 5), MEDLINE and EMBASE (1966 to 2014),

show abstract

Omeprazole Treatment of Children With Peptic Esophagitis Refractory to Ranitidine Therapy

Cited by 55 publications

References 30 publications

A critical appraisal of current management practices for infant regurgitation - recommendations of a working party

A critical appraisal of current management practices for infant regurgitation - recommendations of a working party

Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review

Pharmacological treatment of children with gastro-oesophageal reflux

Contact Info

Product

Resources

About